Evidence map›Paper›PMID 39928965›Full record

ArticleRadiation oncology journal2025

Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response.

Francesco Marampon, Giovanni Luca Gravina, Elisa Cinelli, Lucy Zaccaro, Miriam Tomaciello, Nunzia Di Meglio, Francesco Gentili, Alfonso Cerase, Armando Perrella, Mariya Yavorska and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesco MaramponDepartment of Radiological, Oncological and Pathological Sciences, University of Rome Sapienza, Rome, Italy.
Giovanni Luca GravinaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Elisa CinelliDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Lucy ZaccaroDepartment of Radiological, Oncological and Pathological Sciences, University of Rome Sapienza, Rome, Italy.
Miriam TomacielloDepartment of Radiological, Oncological and Pathological Sciences, University of Rome Sapienza, Rome, Italy.
Nunzia Di MeglioDiagnostic Imaging, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Francesco GentiliDiagnostic Imaging, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Alfonso CeraseUnit of Neuroradiology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Armando PerrellaDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Mariya YavorskaDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Sami AburasDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Luciano MuttiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Maria Antonietta MazzeiDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giuseppe MinnitiDepartment of Radiological, Oncological and Pathological Sciences, University of Rome Sapienza, Rome, Italy.
Paolo TiniDepartment of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNo guidelines exist to delineate radiation therapy (RT) targets for the treatment of multiple glioblastoma (mGBM). This study analyzes margins around the gross tumor volume (GTV) to create a clinical target volume (CTV), comparing response parameters and modalities of recurrence. Material and Methods: One-hundred and three mGBM patients with a CTV margin of 2 cm (GTV + 2.0 cm) or 1 cm (GTV + 1.0 cm) were retrospectively analyzed. All patients received a total dose of 59.4-60 Gy in 1.8-2.0 Gy daily fractions, delivered from 4 to 8 weeks after surgery, concomitantly with temozolomide (75 mg/m2). Overall survival (OS) and progression-free survival (PFS) were calculated from the date of surgery until diagnosis of disease progression performed by magnetic resonance imaging and classified as marginal, in-field, or distant, comparing site of progression with dose distribution in RT plan.

resultsOS in mGBM CTV1 group was 11.2 months (95% confidence interval [CI], 10.3-12.1), and 9.2 months in mGBM CTV2 group (95% CI, 9.0-11.3). PFS in mGBM CTV1 group occurred within 8.3 months (95% CI, 7.3-9.3), and 7.3 months in mGBM CTV2 group (95% CI, 6.4-8.1). No difference was observed between the two groups in terms of OS and PFS time distribution. Adjusted to a multivariate Cox risk model, epidermal growth factor receptor amplification resulted a negative prognostic factor for both OS and PFS.

conclusionIn mGBM, the use of a 1 cm CTV expansion seems feasible as it does not significantly affect oncological outcomes and progression outcome.

Indexed as

Clinical target volumeMultifocal glioblastomaRadiotherapy delineationRecurrence patterns

Identifiers

PMID39928965
PMCPMC12010890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.